Brain circuits driving overeating reveal new obesity treatment targets
Scientists map how brain reward and hunger systems malfunction to cause overeating, offering insights for better obesity treatments.
42 articles
Scientists map how brain reward and hunger systems malfunction to cause overeating, offering insights for better obesity treatments.
Novel GLP-1 analogue NNC5840 achieves greater weight reduction than semaglutide by optimizing receptor signaling bias rather than potency.
New research explores how GLP-1-based drugs like Ozempic and Wegovy work to treat obesity beyond simple appetite suppression.
Expert consensus provides updated recommendations for managing popular weight-loss medications before and after surgery.
New review explains the dual mechanisms behind GLP-1 receptor agonists' dramatic weight loss effects in both central and peripheral systems.
Meta-analysis reveals patients regain substantial weight after discontinuing semaglutide, tirzepatide, and liraglutide therapy.
New research compares two leading GLP-1 medications for obesity treatment, potentially reshaping clinical practice.
Major trial shows oral diabetes drug significantly reduces cardiovascular events in nearly 10,000 high-risk patients over 4 years.
New research shows combining weight-loss medications with hormone therapy could transform health outcomes for obese men with low testosterone.
Major study finds 43% of obesity medications prescribed to teens go unfilled, with Hispanic youth facing greatest barriers to access.
First randomized trial finds weekly semaglutide injections reduced alcohol craving and consumption in adults with alcohol use disorder.
WHO-commissioned reviews find Ozempic and similar drugs deliver up to 16% weight loss, but long-term safety data remains limited.